Diabetes Mellitus, Type 2 Clinical Trial
— DAMPOfficial title:
Effect of Conversation Map on Diabetes Management Self-efficacy and Diabetic Distress Among Type 2DM Patient in Pakistan: A Randomized Controlled Trial
NCT number | NCT03747471 |
Other study ID # | ruby1234 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2019 |
Est. completion date | April 30, 2019 |
Verified date | July 2019 |
Source | Dow University of Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background Diabetes is recognized as an important cause of premature death and disability.
Non-clinical interventions play an important role in the control of diabetes and the
prevention of its associated complications. Traditional methods of educating diabetic
patients to empower them for the control of their disease might not work in the developing
world. However, the novel interactive and pictorial health education tool named Diabetes
Conversation Map (DCM) might be effective for the improvement of diabetes management
self-efficacy and distress among diabetic patients in lower middle income setting of Karachi,
Pakistan.
Objective To assess the effectiveness of DCM as compared to routine care to improve the
diabetes management self-efficacy (DMSE) and diabetic distress (DD) among type 2 diabetic
patients (T2DM) visiting diabetic clinics of tertiary care hospitals in lower middle income
setting of Karachi, Pakistan.
Methodology This will be a two arms randomized controlled trial, conducted in two tertiary
care hospitals, Karachi. A sample of 120 T2DM patients of age 30 - 60 years with sub-optimal
diabetes control will be screened through eligibility criteria and diabetes distress
screening tool. Patients who fulfill the eligibility criteria and have diabetes distress will
be randomized into intervention (n=60) and control group (n=60) using sealed envelopes. The
intervention arm will receive four diabetic education sessions using the DCM in a group of
5-8 participants and each session will be at the interval of one (1) week, by the principal
investigator. T2DM patients in the controlled arm will receive routine care. Data on DMSE and
DD will also be measured 2-3 months post intervention after the completion of all education
sessions. Descriptive statistics will be used for data analysis through SPSS version 20;
whereas, application of Repeated Measures ANOVA will be carried out for inferential
statistics.
Status | Completed |
Enrollment | 120 |
Est. completion date | April 30, 2019 |
Est. primary completion date | February 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - All patients of both gendersage 30-60 years diagnosed with type 2 diabetes mellitusfor at least 5 years, presenting at the diabetes clinics of study setting and considered by health care professional to have a suboptimal management of their disease. - Patient having HbA1c more than 7 will be included - Patients who have not participated in any diabetic educational program before. - Patients who will be found to be diabetes distressed as recommended in diabetes distress (DD) screening tool Exclusion Criteria: - Patients with major disabilities, diagnosed with mental health problems/ cognitive pattern not intact and those with major diabetes related complications. - Patients residing outside of Karachi or intended to leave the city during the study duration will be excluded. |
Country | Name | City | State |
---|---|---|---|
Pakistan | Dow University of Health Sciences | Karachi | Sindh |
Lead Sponsor | Collaborator |
---|---|
Rubina Qasim |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Diabetes Management Self-Efficacy (DMSE) at 3 months: | The change in DMSE will be measured using validated DMSE scale. The scale has 20 items comprised of 4 domains; 1) nutrition specific and weight, 2) medical treatment, 3) physical exercise, 4) blood sugar. Each item is scored on 11 point likert scale (0=completely unable to 10=completely able). Possible score ranges from 0 to 200, with higher score representing higher self-efficacy. | at baseline and after 3 months of enrollment | |
Primary | Change from baseline Diabetes distress (DD) 3 months: | The change in DD will be screened using validated DD scale. The scale has two parts; part 1 is consisting of two items asking about feelings of overburden due to demands of living with diabetes and feelings of failure with diabetes routine; the aim of part 1 is to screen for the presence of DD. Part 1 will be administered before the enrollment of the patient to screen for the presence of DD. If DD is present, part 2 will begin consisting of 17 items to score the extent of DD. Each item is scored on a likert scale ranging from 1 (not a problem) to 6 (a very serious problem). According to the instructions of DDS scoring sheet, total DDS will be measured with mean score while dividing the sum of all items by 17.The mean score of =3 will be the threshold for being distressed. | baseline and 3 months of enrollment | |
Secondary | Change from baseline HbA1C at 3 months: | Change in HbA1c level will be measured at baseline and 3 months after enrollment to see mean difference in the two measurements | baseline and 3 months after enorllment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |